However, the observation that eIF4A inhibition counteracts the induction of PD-L1 by IFN-γ in melanoma, breast and colon cancer cell lines suggests the STAT1 RG4 to be a broad immunomodulator of PD-L1 expression in these cancer types. Here, CD274 is linked to cancer.